Verition Fund Management
KDNY

Verition Fund Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Verition Fund Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,800
Closed -$415K – 2807
2023
Q2 		$415K Buy
+10,800
New +$277K 0.01% 1341

Verition Fund Management's KDNY Position: Q3 2023 in Review

Verition Fund Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 8,510 shares — an estimated $327K sold.

Verition Fund Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $327K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Verition Fund Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 8,510 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $327K.
  • Verition Fund Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Verition Fund Management's Chinook Therapeutics, Inc. Common Stock position peaked at $327K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.